Iron Deficiency Anemia Market Shows Strong Future Potential with Increasing Industry Investments by 2036 - DelveInsight

DelveInsight's "Iron Deficiency Anemia Market Insights, Epidemiology, and Market Forecast-2036′′ report offers an in-depth understanding of the Iron Deficiency Anemia, historical and forecasted epidemiology as well as the Iron Deficiency Anemia market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Iron Deficiency Anemia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Iron Deficiency Anemia Market Forecast
https://www.delveinsight.com/sample-request/iron-deficiency-anemia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gaurav

Some of the key facts of the Iron Deficiency Anemia Market Report:
• The Iron Deficiency Anemia market size was valued at approximately USD 1.6 billion in 2025 and is expected to witness steady growth during the 2026-2036 forecast period, expanding at a compound annual growth rate (CAGR) of approximately 1.5%.
• In May 2026, AMAG Pharmaceuticals announced that the U.S. FDA has approved updated prescribing information for Feraheme (ferumoxytol). The revised label reaffirms its use in adults with iron deficiency anemia (IDA) who are unable to tolerate oral iron therapy or have chronic kidney disease (CKD). The updated prescribing information also continues to emphasize important safety precautions, including monitoring patients for potential hypersensitivity reactions during treatment.
• In March 2026, Shield Therapeutics announced that the European Medicines Agency (EMA), through its Committee for Medicinal Products for Human Use (CHMP), has issued a positive opinion recommending the extension of FERACCRU's indication to include adolescents aged 12 years and older for the treatment of iron deficiency. The company also confirmed that all requirements outlined in its Pediatric Investigation Plan (PIP) have been successfully fulfilled.
• In December 2025, The U.S. FDA has approved a label expansion for ACCRUFER, extending its indication to include adolescents aged 10 years and older for the treatment of iron deficiency. This expanded approval broadens the therapy's eligible patient population beyond its previous indication.
• In December 2025, Shield Therapeutics announced that the U.S. FDA has approved Accrufer (ferric maltol) as the first prescription oral therapy for the treatment of iron deficiency in pediatric patients aged 10 years and older. This approval expands the drug's previous indication, which was limited to adults, making it available to a broader patient population.
• In November 2025, Nemysis Limited has announced the execution of a Subscription Agreement under which Kolinpharma, through its parent company IGEA Holding, has made a strategic investment in the company's share capital. This investment is expected to support Nemysis' ongoing growth and development initiatives.
• Novel oral agents: FERACCRU / ACCRUFER represent next-generation oral therapies designed to enhance iron absorption and tolerability, validating the shift toward mechanism-driven formulations that improve patient compliance and expand use in broader populations.
• Intravenous iron therapies: Products such as INJECTAFER / FERINJECT, and MONOFER deliver rapid and efficient iron repletion, particularly in patients with severe deficiency, chronic diseases, or intolerance to oral therapies, reinforcing their role as key disease-management options.
• According to DelveInsight's estimates, the total prevalent cases of IDA in the 7MM were approximately 31,370,000 in 2025.
• Among the EU4, Germany accounted for the highest number of prevalent cases of IDA, followed by Spain, whereas France accounted for the lowest number of cases in 2025.
• The observed female predominance and earlier onset of IDA highlight the importance of sex-specific screening and early intervention strategies, particularly in recognizing susceptibility patterns and addressing disease at onset to prevent long-term complications.
• The prevalence of anemia was 9.3% in the US population aged 2 years and older. Males had a lower prevalence of anemia than females.
• Key Iron Deficiency Anemia Companies: Pharmacosmos A/S, Nemysis Ltd, Keryx Biopharmaceuticals, Pharmacosmos A/S, Tigermed Consulting Co., Ltd, Shield Therapeutics, Zeria Pharma, Keros Therapeutics, Inc., AMAG Pharma, JW Pharmaceutical, and others
• Key Iron Deficiency Anemia Therapies: Ferric Derisomaltose, Low Dose IHAT, ferric citrate, iron isomaltoside 1000 (Monofer®), Ferric carboxymaltose, Ferric Maltol, Z-213, KER-047, Ferumoxytol, venoferrum(iron sucrose), Z-213, and others
• The Iron Deficiency Anemia epidemiology based on gender analyzed that Iron Deficiency Anemia affects more females as compared to males
• The Iron Deficiency Anemia market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Iron Deficiency Anemia pipeline products will significantly revolutionize the Iron Deficiency Anemia market dynamics.

Iron Deficiency Anemia Overview
Iron Deficiency Anemia (IDA) is a common type of anemia that occurs when the body lacks enough iron to produce hemoglobin, the protein in red blood cells responsible for carrying oxygen throughout the body. Hemoglobin is crucial for delivering oxygen from the lungs to other parts of the body and for returning carbon dioxide from the tissues back to the lungs.

Get a Free sample for the Iron Deficiency Anemia Market Report:
https://www.delveinsight.com/report-store/iron-deficiency-anemia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gaurav

Iron Deficiency Anemia Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2022 to 2036. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Iron Deficiency Anemia Epidemiology Segmentation:
The Iron Deficiency Anemia market report proffers epidemiological analysis for the study period 2022-2036 in the 7MM segmented into:
• Total Prevalent Cases of Iron Deficiency Anemia (IDA)
• Total Diagnosed Prevalent Cases of Iron Deficiency Anemia (IDA)
• Gender-Specific Diagnosed Prevalent Cases of Iron Deficiency Anemia (IDA)
• Pathology-Specific Diagnosed Prevalent Cases of Iron Deficiency Anemia (IDA)
• Severity-specific Diagnosed Prevalent Cases of Iron Deficiency Anemia (IDA)
• Total treated Cases of Iron Deficiency Anemia (IDA)

Download the report to understand which factors are driving Iron Deficiency Anemia epidemiology trends @ Iron Deficiency Anemia Epidemiology Forecast
https://www.delveinsight.com/sample-request/iron-deficiency-anemia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gaurav

Iron Deficiency Anemia Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Iron Deficiency Anemia market or expected to get launched during the study period. The analysis covers Iron Deficiency Anemia market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Iron Deficiency Anemia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Iron Deficiency Anemia Therapies and Key Companies
• Ferric Derisomaltose: Pharmacosmos A/S
• Low Dose IHAT: Nemysis Ltd
• ferric citrate: Keryx Biopharmaceuticals
• iron isomaltoside 1000 (Monofer®): Pharmacosmos A/S
• Ferric carboxymaltose: Tigermed Consulting Co., Ltd
• Ferric Maltol: Shield Therapeutics
• Z-213: Zeria Pharma
• KER-047: Keros Therapeutics, Inc.
• Ferumoxytol: AMAG Pharma
• venoferrum(iron sucrose): JW Pharmaceutical
• Z-213: Zeria Pharma

Discover more about therapies set to grab major Iron Deficiency Anemia market share @ Iron Deficiency Anemia Treatment Market
https://www.delveinsight.com/sample-request/iron-deficiency-anemia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gaurav

Iron Deficiency Anemia Market Drivers
• Rising global prevalence of iron deficiency anemia due to poor nutrition, chronic diseases, pregnancy, and gastrointestinal disorders.
• Increasing awareness and early diagnosis through routine screening programs and public health initiatives.
• Growing adoption of advanced intravenous (IV) iron formulations with improved safety, efficacy, and shorter infusion times.
• Expanding approvals and label extensions for oral and injectable iron therapies across pediatric and adult populations.
• Increasing incidence of chronic kidney disease (CKD), inflammatory bowel disease (IBD), cancer, and heart failure, all of which contribute to iron deficiency anemia.

Iron Deficiency Anemia Market Barriers
• Availability of low-cost generic oral iron supplements, creating pricing pressure for branded therapies.
• Gastrointestinal side effects associated with conventional oral iron treatments, leading to poor treatment adherence.
• Safety concerns related to intravenous iron products, including hypersensitivity reactions and infusion-related adverse events.
• Underdiagnosis and undertreatment of iron deficiency anemia, particularly in low- and middle-income countries.
• Limited awareness among patients regarding the long-term consequences of untreated iron deficiency.

Scope of the Iron Deficiency Anemia Market Report
• Study Period: 2022-2036
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Iron Deficiency Anemia Companies: Pharmacosmos A/S, Nemysis Ltd, Keryx Biopharmaceuticals, Pharmacosmos A/S, Tigermed Consulting Co., Ltd, Shield Therapeutics, Zeria Pharma, Keros Therapeutics, Inc., AMAG Pharma, JW Pharmaceutical, and others
• Key Iron Deficiency Anemia Therapies: Ferric Derisomaltose, Low Dose IHAT, ferric citrate, iron isomaltoside 1000 (Monofer®), Ferric carboxymaltose, Ferric Maltol, Z-213, KER-047, Ferumoxytol, venoferrum(iron sucrose), Z-213, and others
• Iron Deficiency Anemia Therapeutic Assessment: Iron Deficiency Anemia current marketed and Iron Deficiency Anemia emerging therapies
• Iron Deficiency Anemia Market Dynamics: Iron Deficiency Anemia market drivers and Iron Deficiency Anemia market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Iron Deficiency Anemia Unmet Needs, KOL's views, Analyst's views, Iron Deficiency Anemia Market Access and Reimbursement

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.